CME

Global Perspectives on Anti-Vascular Endothelial Growth Factor Therapies: If, When, and How to Switch

Authors: Anat Loewenstein, MD, MHA; Clare Bailey, MD, FRCOphth; Dilsher S. Dhoot, MD; Sophie J. Bakri, MD; Pearse A. Keane, MD, FRCOphth
CME Released: 12/5/2023
Valid for credit through: 12/5/2024, 11:59 PM EST

Credits Available

Non-US Physicians - maximum of 0.50 European CME Credits (ECMEC®)

You Are Eligible For
- Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US retina specialists, general ophthalmologists, other eye care professionals, diabetologists, and all physicians caring for patients with macular diseases.

The goal of this activity is for learners to be better able to select patients who have need of new and emerging anti-vascular endothelial growth factor (anti-VEGF) and bispecific therapies and to use them in clinical practice

Upon completion of this activity, participants will:

Have increased knowledge regarding
- Emerging anti-VEGF and bispecific therapies for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
- Strategies using new and emerging anti-VEGF and bispecific therapies in different patient populations
- Safety monitoring when using new and emerging therapies in nAMD and DME
- Improving patient adherence in nAMD and DME

Disclosures

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.

Faculty

Anat Loewenstein, MD, MHA

Professor of Ophthalmology
Tel Aviv University Medical School
Chairman, Department of Ophthalmology
Tel Aviv Medical Center
Tel Aviv, Israel

Disclosures

Anat Loewenstein, MD, MHA, has the following relevant financial relationships:
Consultant or advisor for: Allergan, Inc.; Annexon; Bayer Healthcare; Beyeonics; Biogen; ForSight Labs; IQVIA; Iveric Bio; Johnson & Johnson Pharmaceutical Research & Development, LLC; Nano Retina; Notal Vision; Novartis; Ocuphire Pharma; OcuTerra; OphtiMedRx; Ripple Therapeutics; Roche; Syneos; Xbrane

Clare Bailey, MD, FRCOphth

Consultant Ophthalmologist
Director of the Retinal Research and Treatment Unit
Bristol Eye Hospital
Bristol, United Kingdom

Disclosures

Clare Bailey, MD, FRCOphth, has the following relevant financial relationships:
Consultant or advisor for: Alimera Sciences; Apellis Pharmaceuticals; Bayer; Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen; Novartis; Roche
Speaker or member of speakers bureau for: Bayer AG; Roche
Research funding from: Bayer AG; Gyroscope; Roche

Dilsher S. Dhoot, MD

Vitreoretinal Surgeon
California Retina Consultants
Retina Consultants of America
Santa Barbara, California, United States

Disclosures

Dilsher S. Dhoot, MD, has the following relevant financial relationships:
Consultant or advisor for: Allergan, Inc.; Alimera Sciences; Apellis Pharmaceuticals; Bausch & Lomb Inc.; Bayer; Coherus; EyePoint; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Ocular Therapeutix; Oxular; Regeneron Pharmaceuticals, Inc.
Speaker or member of speakers bureau for: Apellis Pharmaceuticals; Coherus; EyePoint; Genentech, Inc.; Regeneron Pharmaceuticals, Inc.
Research funding from: Genentech, Inc.; Regeneron Pharmaceuticals, Inc.
Owns stock (privately owned) in: Vortex Surgical
Owns stock (publicly traded) in: Outlook Therapeutics

Sophie J. Bakri, MD

Chair and Professor of Ophthalmology
Vitreoretinal Diseases and Surgery
Mayo Clinic
Rochester, Minnesota, United States

Disclosures

Sophie J. Bakri, MD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie Inc.; Adverum; Allergan, Inc.; Apellis Pharmaceuticals; EyePoint; Ilumen; Iveric Bio; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Outlook Therapeutics; Pixium; Regeneron Pharmaceuticals, Inc.; Revana; Roche; VoxelCloud; Zeiss
Research funding from: Regenxbio

Pearse A. Keane, MD, FRCOphth

Consultant Ophthalmologist
Moorfields Eye Hospital NHS Foundation Trust
Professor of Artificial Medical Intelligence
University College London
London, United Kingdom

Disclosures

Pearse A. Keane, MD, FRCOphth, has the following relevant financial relationships:
Consultant or advisor for: Adecco; Apellis Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; RetinAI; Roche; Thea
Speaker or member of speakers bureau for: AbbVie Inc.; Alimera; Bayer
Stock options from: Bitfount

Editors

Katherine Carpenter, PhD

Medical Education Director, WebMD Global, LLC

Disclosures

Katherine Carpenter, PhD, has the following relevant financial relationships:
Consultant or advisor for: Eisai Inc. (former); GW Pharmaceuticals (former)

Eloise Ballard, PhD

Scientific Content Manager, WebMD Global, LLC

Disclosures

Eloise Ballard, PhD, has no relevant financial relationships.

Compliance Reviewer

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

For Physicians

The Global Perspectives on Anti-Vascular Endothelial Growth Factor Therapies: If, When, and How to Switch made available on https://www.medscape.org/viewarticle/990641 and organized by WebMD Global, LLC is accredited by the European Accreditation Council for Continuing Medical Education (EACCME^®) to provide the following CME activity for medical specialists.

Only those e-learning materials that are displayed on the UEMS-EACCME^® website have formally been accredited.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME^® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME^® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications.

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

Follow these steps to earn European CME Credits (ECMEC®)*:

Read the course description information.
Study the educational content.
Answer the post test questions. Select the single best answer to each question.
To receive a certificate, you must receive a 75% passing score on the post test and complete the evaluation form.
Credit will only be issued during the valid credit period noted on the activity title page.
You may view or print the certificate from your Activity Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your Activity Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the Activity Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education

CME

Global Perspectives on Anti-Vascular Endothelial Growth Factor Therapies: If, When, and How to Switch

Authors: Anat Loewenstein, MD, MHA; Clare Bailey, MD, FRCOphth; Dilsher S. Dhoot, MD; Sophie J. Bakri, MD; Pearse A. Keane, MD, FRCOphthFaculty and Disclosures

CME Released: 12/5/2023

Valid for credit through: 12/5/2024, 11:59 PM EST

processing....

All sections of this activity are required for credit.

Introduction

Dr Loewenstein discusses challenges and approaches in managing retinal disease with anti-VEGFs.
Anat Loewenstein, MD, MHA

Switching Patients With Neovascular AMD and DME

Drs Bailey and Dhoot discuss patient cases suitable for anti-VEGF therapy switches.
Clare Bailey, MD, FRCOphth, and Dilsher S. Dhoot, MD

Treatment-Naive Patients With Neovascular AMD and DME

Drs Bailey and Dhoot discuss the management of treatment-naive patients with neurovascular AMD and DME.
Clare Bailey, MD, FRCOphth, and Dilsher S. Dhoot, MD

Safety and Monitoring for Anti-VEGFs

Dr Bakri explains monitoring approaches to optimize safety for patients having intravitreal anti-VEGF therapy.
Sophie J. Bakri, MD

Addressing Adherence in Patients With AMD and DME

Dr Keane explains some drivers of nonadherence and potential approaches to address these barriers.
Pearse A. Keane, MD, FRCOphth

Conclusion

Dr Loewenstein summarizes the talk series with key takeaways for the program.
Anat Loewenstein, MD, MHA

Educational Impact Challenge

Please answer the questions below to self-assess your knowledge. Answering these questions again after the activity will allow you to see what you learned.

Page 1 of 9

CME Information Download Slides

Activity Transcript

Print
Like Tweet

Activity Transcript

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Anat Loewenstein, MD, MHA

Clare Bailey, MD, FRCOphth

Dilsher S. Dhoot, MD

Sophie J. Bakri, MD

Pearse A. Keane, MD, FRCOphth

Editors

Katherine Carpenter, PhD

Eloise Ballard, PhD

Compliance Reviewer

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

CME

Global Perspectives on Anti-Vascular Endothelial Growth Factor Therapies: If, When, and How to Switch

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

Anat Loewenstein, MD, MHA

Clare Bailey, MD, FRCOphth

Dilsher S. Dhoot, MD

Sophie J. Bakri, MD

Pearse A. Keane, MD, FRCOphth

Editors

Katherine Carpenter, PhD

Eloise Ballard, PhD

Compliance Reviewer

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Global Perspectives on Anti-Vascular Endothelial Growth Factor Therapies: If, When, and How to Switch

All sections of this activity are required for credit.

Introduction

Switching Patients With Neovascular AMD and DME

Treatment-Naive Patients With Neovascular AMD and DME

Safety and Monitoring for Anti-VEGFs

Addressing Adherence in Patients With AMD and DME

Conclusion

Educational Impact Challenge